GlaxoSmithKline is in line for an exit as CureVac files for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.

CureVac, a Germany-based messenger RNA (mRNA) drug developer backed by pharmaceutical firm GlaxoSmithKline (GSK), on Friday filed for an initial public offering on the Nasdaq Global Market with a placeholder target of $100m. The company has not yet set any terms for the proposed offering. Spun out of Eberhard Karls University of Tübingen in 2000,…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.